The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

NCT05931328 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma

Interventions

DRUG: thiotepa combined with pomalidomide

Sponsor

The First Affiliated Hospital with Nanjing Medical University